On 7 October 2026 the Washington Post reported that the Trump administration is preparing a stopgap that would let some previously restricted peptides be sold temporarily through compounding pharmacies while the FDA writes permanent rules. Within hours the headline had become "BPC-157 is legal again" on half the peptide forums on the internet.
It isn't. Not yet, and maybe not in the form people expect. The report rests on two unnamed sources, the plan has not been announced, and nobody outside government knows which peptides it would cover. So what was actually reported, what is already decided, what would change if the plan goes ahead, and what does it mean for the vial you can buy today? Let's dive in.
TLDR
What happened? The Washington Post reported on 7 October that officials are drafting a temporary arrangement letting some compounding pharmacies dispense restricted peptides while formal rulemaking runs. HHS did not comment. The plan is unannounced, its timing is unclear, and the peptide list is unknown.
What is already decided: In April 2026 the FDA removed 12 peptides from its Category 2 "significant safety risks" list. In July an FDA advisory committee recommended six peptides for the 503A Bulks List, against the advice of the FDA's own scientists. Neither step made any of them legal to compound.
What would change: Most likely the FDA would announce "enforcement discretion": it would not act against licensed pharmacies compounding certain peptides on a prescription. That is a policy, not a law, and it can be withdrawn.
Safety: No peptide in this group has completed a human trial that shows it works for the condition it was reviewed for. FDA reviewers found no human exposure data at all for several of them.
Legal Status (October 2026): None of these peptides is FDA approved or on the 503A Bulks List. Compounding them is still unauthorized, and "research use only" vials are still not legal to sell for human use.
What the Washington Post Actually Reported
Here is the report, stripped to what it says. Two people familiar with the matter told the Post that the administration is preparing a temporary route for some previously restricted peptides to be sold through compounding pharmacies while federal health officials write new regulations (Washington Post, 7 October 2026). The Post was clear that the plan had not been announced, that its timing was unclear, that it could still change, and that it was not known which peptides would be included (as summarised by Becker's Hospital Review, October 2026).
Officials are reportedly discussing guardrails: patient disclosures, reporting of serious adverse events, and collection of data on how the peptides are used. Those conditions match what the Alliance for Pharmacy Compounding has been asking for. Its chief executive, Scott Brunner, told the Post the group has asked the FDA for interim enforcement discretion under exactly those terms, and called it a better approach than illicit markets.
Ilisa Bernstein, a former deputy director of the FDA's drug compliance office, gave the Post the most realistic read of the situation. She has concerns about the lack of safety data, but broader access seems inevitable, and guardrails could at least help identify safety problems.
The report describes a plan in draft. It does not describe a decision, a date, or a list.
How We Got Here: The 2026 Timeline
This did not come out of nowhere. The October report is the latest step in a sequence that started in 2023.
| Date | What happened | Legal effect |
|---|---|---|
| Sept 2023 | FDA places a batch of popular peptides, including BPC-157, TB-500 and others, in Category 2 of its interim compounding policy, citing "significant safety risks" | Pharmacies told not to compound them |
| 27 Feb 2026 | HHS Secretary Robert F. Kennedy Jr. says on The Joe Rogan Experience that action on about 14 peptides is coming "within a couple of weeks" | None |
| 15 Apr 2026 | FDA announces it will remove 12 peptides from Category 2 because their nominators withdrew, and schedules advisory committee meetings | Safety label removed; peptides left in a gray zone, not authorized |
| June 2026 | Eight new members appointed to the Pharmacy Compounding Advisory Committee | None |
| 23–24 Jul 2026 | Committee recommends six of seven peptides for the 503A Bulks List; FDA staff had opposed all seven | Advisory only |
| 7 Oct 2026 | Washington Post reports a temporary-sale plan in draft | None yet |
The April step is the one most often misread. The FDA's own Category 2 page now lists BPC-157, TB-500, KPV, MOTS-c, semax, epitalon, emideltide and others under "nominated but withdrawn", with the original safety language still attached (FDA, Category 2 page, content current 22 April 2026). As the law firm Orrick put it at the time, removal from Category 2 "does not, by itself, place these substances on the 503A bulks list or into Category 1", which is the only category where the FDA exercises enforcement discretion (Orrick, 16 April 2026).
For the full vote-by-vote record of the July meeting, see our FDA peptide update from July 2026.
How a "Temporary Sale" Would Actually Work
Let's get this straight. The FDA has no mechanism called "temporary sale". What the Post describes almost certainly means enforcement discretion, and it helps to know what that is and isn't.
The permanent route: the 503A Bulks List
Section 503A of the Food, Drug, and Cosmetic Act lets state-licensed pharmacies compound a drug for a named patient on a prescription. A bulk ingredient they use has to meet one of three tests: it has a USP monograph, it is part of an FDA-approved drug, or it is on the 503A Bulks List. That list lives in federal regulation at 21 CFR 216.23 and can only be changed by formal notice-and-comment rulemaking. Compounding attorneys have estimated 12 to 24 months for that process. No deadline forces the FDA to start it.
The fast route: enforcement discretion
While a substance is under evaluation, the FDA sorts it into categories under its interim policy. Category 1 means the agency has not identified significant safety risks and will not take action against pharmacies that compound it while the review continues. Putting the peptides in Category 1, or announcing in some other way that it will not enforce, is a matter of weeks. It needs no rulemaking.
Brunner predicted this in July: if the agency accepts the committee's advice, it is "possible, maybe even likely" that it will announce a period of enforcement discretion pending formal rulemaking (CNN, 31 July 2026). The October report suggests that is the route being drafted.
Enforcement discretion is a promise not to prosecute, not a grant of legality. A future FDA can withdraw it with a web page update.
Gray Market vs Compounded vs Approved: What Would Change
If the plan goes ahead, the change is narrower than the headlines suggest. It opens one channel, prescription compounding, and leaves everything else as it is.
| Gray market ("research use only") | Compounded under enforcement discretion | On the 503A Bulks List | FDA-approved drug | |
|---|---|---|---|---|
| Legal to sell for human use? | No | Tolerated, not authorized | Yes, by prescription | Yes |
| Prescription needed? | No | Yes | Yes | Yes |
| Who makes it? | Unknown, often overseas | State-licensed 503A pharmacy | State-licensed 503A pharmacy | Approved manufacturer under cGMP |
| Ingredient quality | Vendor certificate, often unverified | Pharmaceutical-grade ingredient from an FDA-registered maker expected | Same | Fully specified and inspected |
| Proven to work? | No | No | No | Yes, for the labelled use |
| Can be reversed quickly? | n/a | Yes | Only by new rulemaking | Only by withdrawal process |
Two things in that table get missed. First, compounding does not create efficacy evidence. A BPC-157 injection from a licensed pharmacy carries exactly as much proof of benefit as one from a gray-market vial. What improves is the odds that the vial contains what the label says, in a sterile form. Second, the gray market does not become legal. A vendor shipping "research use only" vials to consumers is in the same position on 8 October as it was on 6 October. Our article on the Paradigm Peptides case shows how that ends when prosecutors decide to act.
Which Peptides Could Be Included
The Post said the list is unknown. The obvious candidates are the six the committee recommended in July. Each vote was tied to one specific medical use chosen by the FDA, not to general use.
| Peptide | Use the committee reviewed | July 2026 vote | FDA's note on human data (Category 2 page) | Status today |
|---|---|---|---|---|
| BPC-157 | Ulcerative colitis | Recommended 8–6, 1 abstention | "No, or only limited, safety-related information" | Not authorized |
| KPV | Wound healing, inflammatory conditions | Recommended 8–6, 1 abstention | No human exposure data identified | Not authorized |
| TB-500 | Wound healing | Recommended 8–6, 1 abstention | No human exposure data identified | Not authorized |
| MOTS-c | Obesity, osteoporosis | Recommended 7–5, 2 abstentions | No human exposure data identified | Not authorized |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Recommended 8–5, 1 abstention | "No, or limited, safety-related information" | Not authorized |
| Epitalon | Insomnia | Recommended 7–4, 1 abstention | No safety information for the proposed route | Not authorized |
| Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | Rejected 7–6, 1 abstention | No safety information for the proposed route | Not authorized |
The use matters more than it looks. A positive vote on BPC-157 was a vote about ulcerative colitis. It carries no finding about tendons, joints or the gym injuries that drive almost all of the demand. If enforcement discretion follows the committee's framing, a prescriber writing BPC-157 for a shoulder would be outside even the tolerated use.
The rest of the April list, including GHK-Cu, LL-37, dihexa, melanotan II and PEG-MGF, has not yet been before the committee. The April Federal Register notice promised a second meeting before the end of February 2027 (Federal Register 2026-07361). A temporary policy covering peptides the committee has never reviewed would be a much bigger step, and nothing reported so far suggests it.
What the Evidence Actually Shows
Here's the caveat that gets dropped. FDA scientists reviewed all seven peptides and proposed that every one of them NOT be added to the list. The agency's July briefing document lists that proposal for both the free-base and acetate form of each substance (FDA briefing document, PCAC, 23–24 July 2026). The agency also noted that every original nominator had withdrawn, and that it chose to bring the substances to the committee anyway.
The staff objections fell into three groups: human studies that were small, short or entirely absent; the risk of immune reactions to injected synthetic peptides; and the difficulty of writing a quality standard for a substance that is sold under one name but varies in composition from supplier to supplier.
| Type of evidence | What exists | Status |
|---|---|---|
| Human trials for the reviewed use, published | None that FDA reviewers found adequate for any of the seven | Gap |
| Animal and cell studies | Substantial for BPC-157, TB-500's parent protein and KPV; thinner for the rest | Published, preclinical |
| Russian clinical use (semax, epitalon) | Decades of use and studies, mostly from a small number of research groups | Published, not replicated to FDA standards |
| Clinic and user reports | Large and growing | Anecdotal, unpublished |
Committee members who voted yes mostly did not argue that the evidence was strong. They argued that the gray market is the bigger danger. "Keeping this in a regulated pharmacy is not the risk in the room. The gray market pipeline is," said member Dr. Hal Mohammed (CNN, 31 July 2026). That is a public-health argument about harm reduction, not a finding that the peptides work.
The case for the plan is about where people get peptides, not about whether peptides do what they are bought for. Those are two separate questions.
What About Dosing?
If the policy arrives, compounded peptides will come with a prescriber's dose on the label. That sounds like an upgrade, and on purity it is. On dosing it changes less than you'd hope: no validated human dosing protocol exists for any of these seven peptides for the uses they were reviewed for, let alone the uses people actually want. A prescriber would be working from the same animal data and community practice you can read about in our compound guides.
What a pharmacy vial should fix is the arithmetic, because the concentration on the label should be the concentration in the vial. The reconstitution maths is the same either way:
| Vial | Water added | Concentration | 250 mcg dose | On a U-100 insulin syringe |
|---|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL (2,500 mcg/mL) | 0.10 mL | 10 units |
| 5 mg | 1 mL | 5 mg/mL (5,000 mcg/mL) | 0.05 mL | 5 units |
| 10 mg | 2 mL | 5 mg/mL (5,000 mcg/mL) | 0.05 mL | 5 units |
Run your own numbers with the reconstitution calculator and the dosage calculator. For the community ranges on a specific compound, see our BPC-157 dosage protocol and TB-500 dosage protocol. Those ranges are user reports, not trial results.
Side Effects and the Gray-Market Harm Record
The documented harms from these peptides come almost entirely from what was in the vial and how it was given, not from the peptide sequence itself. That is the strongest argument for moving supply into pharmacies, and it is worth looking at honestly.
RAADFest, Las Vegas, July 2025
Two women were injected with peptides at a booth at an anti-aging festival in Las Vegas. Both left in ambulances and had to be intubated. They recovered. The Nevada Pharmacy Board could not determine why they became ill, because investigators were never able to obtain the product to test it. In early 2026 the board fined a California-licensed doctor and pharmacist $10,000 each for practising in Nevada without a licence, a self-described health coach $5,000, and a Texas private membership association $10,000 for allegedly mailing the peptides to the venue (ProPublica, 2026). According to the board's citations, the injections included at least one peptide on the FDA's risk list.
The supply chain
A June 2026 Chainalysis report, summarised by Becker's, found cryptocurrency payments to gray-market peptide vendors on pace for a $100 million annual run rate in 2026, up from roughly $1 million a quarter in 2024. Spending on independent purity testing per buyer fell an estimated 88%, as buyers leaned on vendor certificates that often don't test for sterility. Two named suppliers had previously been identified as fentanyl and amphetamine precursor suppliers (Becker's Hospital Review, 7 July 2026).
What the safety groups say
ECRI and the Institute for Safe Medication Practices responded to the July vote by pointing to unresolved risks: immune reactions to repeated injections, manufacturing impurities that make the body treat the product as foreign, and possible tumour growth in people with undiagnosed cancer from growth-promoting and angiogenic peptides (ECRI and ISMP, 24 July 2026). Our TB-500 side effects and cancer risk article explains why that last concern is real in principle and unproven in practice.
Pharmacy compounding addresses the contamination risk. It does nothing about the immune and long-term risks, which come from the peptide itself.
The Legal and Regulatory Situation
As of 8 October 2026, here is where things stand:
- None of these peptides is an FDA-approved drug.
- None is on the 503A Bulks List, and no rulemaking to add them has been published.
- None has been placed in Category 1, so no formal enforcement discretion applies.
- The FDA has made no announcement confirming the Post's report, and HHS did not comment.
- BPC-157 and TB-500 remain prohibited by the World Anti-Doping Agency, whatever the FDA does.
The policy also runs against the FDA's direction on another peptide class. In April the agency proposed excluding semaglutide, tirzepatide and liraglutide from the bulks list for outsourcing facilities, as part of its crackdown on compounded GLP-1s (Becker's Hospital Review, October 2026). Loosening access to unapproved wellness peptides while tightening it for approved weight-loss peptides is an unusual combination, and it invites legal challenge. Other industries are watching closely: STAT reported on 5 October that stem cell entrepreneurs see the FDA's peptide approach as a model for themselves (STAT, 5 October 2026).
The Honest Take
If the plan happens, it will probably make peptide use somewhat safer for people who were going to inject peptides anyway. A sterile vial from a licensed pharmacy, made from an ingredient with a real certificate of analysis, is better than a powder from a crypto-only vendor whose purity report may be fake. That is a real benefit, and the people arguing for it are not wrong about the gray market.
What it will not do is tell you whether any of these peptides works. The FDA's own scientists looked at the evidence for all seven and said no to all seven. A committee overruled them on access, not on efficacy. A prescription label will give a peptide the look of an approved medicine without the evidence behind one, and that is the part worth keeping in mind.
And until an announcement actually appears on fda.gov, nothing has changed. Anyone telling you this week that BPC-157 is "legal now" is selling something.
FAQ
Are peptides legal now after the Washington Post report?
No. The report describes a plan in draft. No FDA policy, rule or list has been published, and the restricted peptides remain unauthorized for compounding.
Which peptides would the temporary sale plan cover?
Unknown. The Post said the list had not been decided. The six peptides recommended in July (BPC-157, KPV, TB-500, MOTS-c, semax and epitalon) are the likeliest candidates.
Is BPC-157 legal?
Not as a drug for human use. It is not FDA approved, not on the 503A Bulks List and not in Category 1. It was removed from the Category 2 safety list in April 2026, which ended the "significant safety risk" label but did not authorize compounding.
What is enforcement discretion?
A statement by the FDA that it will not take action against a defined activity, here licensed pharmacies compounding certain peptides on prescription, while a formal rule is written. It is fast to introduce and just as fast to withdraw.
Will I need a prescription?
Yes. Section 503A compounding is always for a named patient on a prescription. The plan would not allow over-the-counter or direct-to-consumer sale.
Does this make "research use only" peptide sites legal?
No. Selling peptides for human use without approval stays illegal whatever the FDA does on compounding. If anything, a legal pharmacy channel gives regulators a stronger reason to go after unlicensed sellers.
When will the FDA decide?
There is no deadline. Enforcement discretion could arrive in weeks. Formal rulemaking to add peptides to the 503A Bulks List is estimated at 12 to 24 months from the July vote.
Will insurance cover compounded peptides?
Almost certainly not. Insurers rarely cover compounded drugs without an approved indication, so expect to pay out of pocket.
Why did FDA scientists oppose the peptides?
The agency's reviewers cited thin or absent human evidence, the risk of immune reactions to injected synthetic peptides, and the difficulty of setting quality standards for substances that vary between suppliers.
Are compounded peptides safer than gray-market peptides?
On contamination and dose accuracy, very likely yes. On whether the peptide itself is safe and effective over the long term, no. Compounding does not generate that evidence.
Resources
Washington Post (2026), "Trump administration paving way for temporary sale of some unapproved peptides", 7 October 2026 — https://www.washingtonpost.com/health/2026/10/07/trump-administration-paving-way-temporary-sale-some-unapproved-peptides/
Becker's Hospital Review (2026), summary of the Post report with Brunner and Bernstein quotes — https://www.beckershospitalreview.com/glp-1s/hhs-plans-stopgap-to-allow-sales-of-some-unapproved-peptides-washington-post/
FDA (2026), Category 2 bulk drug substances, including the "nominated but withdrawn" peptide list, content current 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Federal Register (2026), Pharmacy Compounding Advisory Committee notice of meeting, document 2026-07361, 16 April 2026 — https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
FDA (2026), July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA (2026), Briefing document, PCAC meeting 23–24 July 2026, with the agency's proposal against all seven substances — https://www.fda.gov/media/193342/download
eCFR (current), 21 CFR 216.23, the 503A Bulks List — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
Orrick (2026), "FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings", 16 April 2026 — https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
The FDA Law Blog (2026), July PCAC vote counts — https://www.thefdalawblog.com/2026/07/peptide-l-wave-pcac-approves-four-bulk-drug-substances-for-the-503a-list/
CNN (2026), "FDA advisers support easing restrictions on six peptides", 31 July 2026 — https://www.cnn.com/2026/07/31/health/what-are-peptides-fda-next-steps-wellness
ECRI and ISMP (2026), statement in response to the PCAC decision, 24 July 2026 — https://home.ecri.org/blogs/ecri-news/ecri-ismp-statements-in-response-to-pcac-decision-on-wellness-peptides
ProPublica (2026), Nevada fines over RAADFest peptide injections — https://www.propublica.org/article/raadfest-peptide-injections-nevada-fines
The Nevada Independent / ProPublica (2025), original RAADFest report — https://thenevadaindependent.com/article/a-las-vegas-festival-promised-ways-to-cheat-death-two-attendees-left-fighting-for-their-lives
Becker's Hospital Review (2026), "The $100M 'gray market' of peptides: 5 notes", Chainalysis findings, 7 July 2026 — https://www.beckershospitalreview.com/glp-1s/the-100m-gray-market-of-peptides-5-notes/
NPR (2026), "The wellness world is eager for RFK Jr.'s promised move on peptides", 31 March 2026 — https://www.npr.org/2026/03/31/nx-s1-5768206/peptides-rfk-fda-compounding-pharmacies
STAT (2026), stem cell industry and the FDA's peptide approach, 5 October 2026 — https://www.statnews.com/2026/10/05/stem-cell-industry-seeks-fda-regulation-like-peptides/
